The Zhitong Finance app learned that Yidu Technology (02158) rose more than 8%, and at press time, it rose 8.19% to HK$5.15, with a turnover of HK$1.06 million.

Financial reports show that in the first half of fiscal year 2024, Yidu Technology's gross margin reached 38.2%, up 12.1 percentage points year on year, a record high; total operating expenses as a percentage of revenue fell 12.8 percentage points year on year, and adjusted net loss narrowed sharply by 75.9% year on year to 54.1 million yuan. After the results, Citigroup, Yamato, and Goldman Sachs successively released research reports, all of which gave Yidu Technology a “buy” rating. The target prices given by the three major banks are all significantly higher than the current stock price of the company.

Citi pointed out that the deep insight and knowledge accumulated by the “intelligent medical brain” yiduCore is the core competitive advantage of Yidu Technology. Yamato said that the increase in gross margin and the sharp narrowing of adjusted net losses of Yidu Technology are better than the general expectations of the market, and it is expected that the company's large-scale model initiatives in the medical vertical field will promote customer acquisition and retention. Goldman Sachs, on the other hand, believes that Yidu Technology's performance in the first half of fiscal year 2024 is “a steady gross margin trend and strict operational control.”